Videos

CBEx Advisory Board Member Ira Klein, MD, VP of Medical Affairs for Tempus Labs, provides an inside look into featured session "AI in Cancer Care: Separating Fact from Fiction."

Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.

Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.

Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...

Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...

Patricia Santos, MD, Memorial Sloan Kettering Cancer Center, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about her research on the coverage and affordability of health care access for adult immigrant cancer...

Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.

Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.

Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...